A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design

(2011) Darren R. Feldman et al.   CANCER

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

(2011) L. S. Rosen et al.   CLINICAL CANCER RESEARCH

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

(2011) A. A. Adjei et al.   ONCOLOGIST

The role of the c-Met pathway in lung cancer and the potential for targeted therapy

(2011) Martin Sattler et al.   Therapeutic Advances in Medical Oncology

Targeting the HGF/Met signalling pathway in cancer

(2010) Fabiola Cecchi et al.   EUROPEAN JOURNAL OF CANCER

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER